- World Health Organization estimations for preventable hepatitis deemed to be beneficial
- Rising penetration of global players to make Asia Pacific prominent region in the near future
ALBANY, N.Y., March 16, 2021 /PRNewswire/ -- Most commonly caused by a group of viruses known as the hepatitis viruses, hepatitis is an inflammation of the liver that can cause a number of health problems and can even lead to death. There are five main strains of the hepatitis virus, namely type A, B, C, D, and E. While all strains of hepatitis viruses causes liver disease, each type of virus strain is related to different severity of the illness. In particular, type B and type C are related to chronic diseases of the liver, cancer and viral hepatitis-related fatalities. According to statistics published by the World Health Organization, hepatitis B and/or C is prevalent in approximately 325 million people worldwide, and for most testing and treatment is beyond reach.
The prevalence of hepatitis in such large numbers across the world calls for well-grounded line of treatment for treatment of the disease to give birth to the hepatitis therapeutics market. While hepatitis can go unnoticed for years, especially for chronic hepatitis, blood examination of individuals at high risk of the disease can help with early detection.
Some types of hepatitis is preventable too. According to a WHO study, by 2030, an estimated 4.5 million premature fatalities can be prevented in low-and middle-income countries through vaccination, diagnostic tests, medication, and education campaigns. This opens vistas for the hepatitis therapeutics market to attain such goals.
Request for Analysis of COVID-19 Impact on Hepatitis Therapeutics Market - https://www.transparencymarketresearch.com/covid19.php
Key Findings of Hepatitis Therapeutics Market Research Report
Hepatitis C Disease Segment holds Higher Revenue Share high among other Key Types of the Disease
The hepatitis C disease type in the hepatitis therapeutics market is projected to account for leading share among other key types of the disease. This is mainly related to the high prevalence of hepatitis C in both developed and developing regions. According to statistics of the World Health Organization, in 2017, an estimated 71 million people were living with chronic hepatitis C.
R&D for advanced therapeutics and effective management of hepatitis C undertaken by leading players is another key factor for the leading share of hepatitis C disease segment.
However, hepatitis B disease type is projected to expand at a notable growth rate due to high mortality associated with strain B of the hepatitis virus.
Request Brochure of Hepatitis Therapeutics Market Report - https://www.transparencymarketresearch.com/brochure.php
Investments in Multi-class Combination Drugs to yield Profits
Among a number of key segments based on drug class, the multi-class combination segment is predicted to expand at a notable CAGR in the forthcoming years. Factors such as increasing prevalence of viraemic diseases, and focus of industry players on the development of combinational therapy due to their efficacy and fewer side-effects is spurring demand for multi-class combination drugs. Epclusa and Mavyret are some combination drugs for hepatitis recently approved by the U.S. FDA.
Hepatitis Therapeutics Market - Prominent Trend
- High correlation of viral hepatitis with morbidity and mortality in populations that raises public concerns steers growth
Purchase the Hepatitis Therapeutics Market Report - https://www.transparencymarketresearch.com/checkout.php
Hepatitis Therapeutics Market - Regional Landscape
Powered by the U.S., North America is at the forefront among other key regions in the global hepatitis therapeutics market. High mortality related to hepatitis and increasing spending on drugs for treatment of the disease in the country spell growth in the hepatitis therapeutics market of North America.
Asia Pacific is predicted to emerge as a key region in the hepatitis therapeutics market in the forthcoming years. Increasing incidence of chronic hepatitis C in developing countries such as India, increasing penetration of global players, and government initiatives to create awareness for hepatitis are creating opportunities in the hepatitis therapeutics market of the region.
Request for Custom Research - https://www.transparencymarketresearch.com/custom-research.php
Hepatitis Therapeutics Market - Key Players
- Gilead Sciences Inc.
- F. Hoffmann - La Roche Ltd
- LAURUS Labs
- AbbVie Inc.
- Hetero Healthcare Limited
- Bristol Myers Squibb
- Merck & Co. Inc.
- Zydus Cadila
- Cipla inc.
- NATCO Pharma Limited
Explore Transparency Market Research's award-winning coverage of the global Healthcare Industry:
Kinase Inhibitors Market: https://www.transparencymarketresearch.com/kinase-inhibitors.html
Arthritis Therapeutics Market: https://www.transparencymarketresearch.com/arthritis-therapeutics-market.html
About Us
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision."
Browse More Upcoming Reports by Transparency Market Research: https://www.transparencymarketresearch.com/upcoming.htm
Contact
Mr. Rohit Bhisey
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Press Release Source: https://www.transparencymarketresearch.com/pressrelease/hepatitis-therapeutics-market.htm
Website: https://www.transparencymarketresearch.com/
Logo: https://mma.prnewswire.com/media/1085206/Transparency_Market_Research_Logo.jpg
